Top ▲
Target not currently curated in GtoImmuPdb
Target id: 2005
Nomenclature: doublecortin like kinase 1
Abbreviated Name: DCAMKL1
Family: DCAMKL family
Gene and Protein Information ![]() |
||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 740 | 13q13.3 | DCLK1 | doublecortin like kinase 1 | |
Mouse | - | 756 | 3 C | Dclk1 | doublecortin-like kinase 1 | |
Rat | - | 433 | 2q26 | Dclk1 | doublecortin-like kinase 1 |
Database Links ![]() |
|
Alphafold | O15075 (Hs), Q9JLM8 (Mm), O08875 (Rn) |
BRENDA | 2.7.11.1 |
CATH/Gene3D | 3.10.20.230 |
ChEMBL Target | CHEMBL5683 (Hs) |
Ensembl Gene | ENSG00000133083 (Hs), ENSMUSG00000027797 (Mm), ENSRNOG00000032922 (Rn) |
Entrez Gene | 9201 (Hs), 13175 (Mm), 83825 (Rn) |
Human Protein Atlas | ENSG00000133083 (Hs) |
KEGG Enzyme | 2.7.11.1 |
KEGG Gene | hsa:9201 (Hs), mmu:13175 (Mm), rno:83825 (Rn) |
OMIM | 604742 (Hs) |
Pharos | O15075 (Hs) |
RefSeq Nucleotide | NM_001195415 (Hs), NM_001111051 (Mm), NM_053343 (Rn) |
RefSeq Protein | NP_004725 (Hs), NP_001104521 (Mm), NP_445795 (Rn) |
UniProtKB | O15075 (Hs), Q9JLM8 (Mm), O08875 (Rn) |
Wikipedia | DCLK1 (Hs) |
Selected 3D Structures ![]() |
|||||||||||
![]() |
|
Enzyme Reaction ![]() |
||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibitor Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1μM compound 5g [PMID 20483621] inhibits DCLK1 activity by approximately 90% [4]. |
DiscoveRx KINOMEscan® screen ![]() |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A screen of 72 inhibitors against 456 human kinases. Quantitative data were derived using DiscoveRx KINOMEscan® platform. http://www.discoverx.com/services/drug-discovery-development-services/kinase-profiling/kinomescan Reference: 1,5 |
![]() ![]() |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Target used in screen: DCAMKL1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Displaying the top 10 most potent ligands View all ligands in screen » |
1. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK, Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol, 29 (11): 1046-51. [PMID:22037378]
2. Ferguson FM, Nabet B, Raghavan S, Liu Y, Leggett AL, Kuljanin M, Kalekar RL, Yang A, He S, Wang J et al.. (2020) Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol, 16 (6): 635-643. [PMID:32251410]
3. Kim MH, Cierpicki T, Derewenda U, Krowarsch D, Feng Y, Devedjiev Y, Dauter Z, Walsh CA, Otlewski J, Bushweller JH et al.. (2003) The DCX-domain tandems of doublecortin and doublecortin-like kinase. Nat Struct Biol, 10 (5): 324-33. [PMID:12692530]
4. Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA et al.. (2010) Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase. Bioorg Med Chem, 18 (12): 4351-62. [PMID:20483621]
5. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC, Zarrinkar PP et al.. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem Biol, 17 (11): 1241-9. [PMID:21095574]
DCAMKL family: doublecortin like kinase 1. Last modified on 14/07/2020. Accessed on 13/02/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2005.